Abstract

Animal lifespan studies are foundational to developing interventions against the biological aging process. In recent years, there has been rising interest in characterizing the effects of longevity therapeutics on health span. Frailty indexes, originally developed to assess clinical frailty in aging humans, have shown promise as measurements of biological age and have been adopted for use in rodent aging biology. This Perspective looks at the current state of rodent frailty indexes and how they are implemented. The differences in frailty parameters used to calculate these indexes have led to inconsistencies between studies defining frailty. In this Perspective, we have highlighted those differences and made recommendations for implementing protocols for frailty index measurement.